IL6 and myeloid sarcoma: Dimethyl fumarate reduces MG activation induced by lipopolysaccharide (LPS) by reducing TNF-α, IL-1β, IL-6, and nitric oxide synthesis, thereby inhibiting MG-associated inflammatory mediator release and relieving MS symptoms [25].